TherOx, based in Irvine, CA, is a pioneering medical company that offers SuperSaturated Oxygen (SSO2) Therapy, the first FDA-approved catheter-based therapy designed to reduce infarct size in patients who have experienced an acute myocardial infarction (AMI). This innovative therapy delivers localized hyperoxemic levels of oxygen to the ischemic myocardium, without affecting door-to-balloon time, resulting in a significant reduction in infarct size and improved left ventricular function. Clinical studies have shown that SSO2 Therapy not only reduces the risk of heart failure but also lowers the rate of all-cause death and hospitalization for heart failure at one year.
With a focus on harnessing the healing power of oxygen, TherOx's SSO2 Therapy has been proven to restore microvascular flow, reduce endothelial swelling, and promote the reperfusion of ischemic myocardium. The therapy has demonstrated a remarkable 26% relative reduction in infarct size, leading to a corresponding 25% reduction in both death and heart failure hospitalization at one year. By providing a groundbreaking solution for patients at risk of heart failure following an AMI, TherOx is revolutionizing STEMI care and offering hope for a healthier future.
Generated from the website